手机购彩

Hengrui PD-1 treatment of Chinese liver cancer data published in the "Lancet · Oncology"
On February 26, local time in the United Kingdom, the results of a study on carrelizumab monotherapy for advanced treated liver cancer led by liver cancer oncologists Professor Qin Shuzheng and Professor Ren Zhenggang were officially published in "Lancet Oncology", objective The response rate was 14.7%, the 6-month survival rate was 74.4%, the 12-month survival rate was 55.9%, and the median survival time was 13.8 months. This is the first summit of "Lancet Tumor ...
2020-02-28
Hengrui Medicine donates another 3 million yuan worth of innovative medicine to aid Hubei
At present, the epidemic of new crown pneumonia in many places such as Wuhan, Hubei, the severe prevention and control situation, and shortage of medical resources have aroused great concern from the society. Under the epidemic, the normal medical needs of special populations such as cancer patients also need to be protected urgently. Recently, Hengrui Medicine launched the "Escort for Hubei Cancer Patients" charity project, which will donate an innovative drug sulfur with a market value of more than 3 million yuan to cancer patients in Hubei Province who need treatment ...
2020-02-18
China's self-developed anti-cancer drug pirlotinib once again tops international top magazines
Today, the Phase II clinical study of the national class 1.1 anti-tumor innovative drug pirlotinib, completed by the director of the National Cancer Center / Xu Binghe of the Cancer Hospital of the Chinese Academy of Medical Sciences and supported by the national major new drug creation program, was formally published in JCO. American Journal of Clinical Oncology), impact factor 28.245 points
2019-08-23
New breakthrough in nasopharyngeal cancer treatment
Xinhuanet, Beijing, September 29 (Wang Kunshuo) China is a high incidence of nasopharyngeal cancer. According to WHO data, China's nasopharyngeal cancer patients rank first in the world. Among them, the incidence of Guangdong is more than five times the national average, so nasopharyngeal cancer is known as "Guangdong cancer". Recently, new treatments have been made for this high-risk cancer in China.
2018-10-08
Chinese HER2-positive advanced breast cancer targeted drug research breakthrough
According to the information from the website of the State Drug Administration on the 16th, China's self-developed new drug for treating relapsed or metastatic breast cancer, pirlotinib maleate (Ireni), was approved for marketing.
2018-08-18
Made in Jiangsu: Decades of Deep Plowing Industry Drive Innovation to Climb "Everest"
China News Network, Jiangsu News, July 24 (Reporter Yu Congwen) Xugong has been focusing on construction machinery manufacturing for 40 years, and regards the top three companies in the world's construction machinery manufacturing industry as "Everest summit"; Hengrui Medicine has no heart for 48 years Poon focuses on medicines and has invested billions of yuan in innovative research and development, in order to establish a national pharmaceutical brand and relieve the suffering of Chinese people. Recently, the reporter followed the "reform and set out to develop high quality ...
2018-07-25
How did Hengrui Medicine turn into an innovative medicine leader A-share medicine “how to make a brother in market value”?
In the A-share market, there is such a "white horse" company: In the 17 years since its listing, net profit has only slightly decreased by 2.17% in 2002, and the remaining 16 years have achieved positive growth, with a compound annual growth rate of 25.94%; in the last 10 years, net asset income The rate has been kept above 21%, and the profitability is very eye-catching. In 2016, it was selected as "the first batch of national top 100 innovative companies in pilot projects" and became the only one of the first 9 innovative companies ...
2018-07-04